The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer

Theodoros Rampias1, Dimitris Karagiannis1, Margaritis Avgeris2

  • 1Biomedical Research Foundation Academy of Athens, Athens, Greece.

EMBO Reports
|January 23, 2019
PubMed

Insights

Low lysine-specific methyltransferase 2C (KMT2C) expression in bladder cancer impairs DNA repair, increasing genomic instability. This suggests KMT2C-deficient tumors are vulnerable to PARP1/2 inhibitors like olaparib.

Area of Science:

  • Oncology
  • Epigenetics
  • DNA Repair

Background:

  • Chromatin-modifying proteins are frequently mutated in human cancers.
  • Lysine-specific methyltransferase 2C (KMT2C/MLL3) is implicated as a tumor suppressor in various cell types.

Purpose of the Study:

  • To investigate the role of KMT2C in bladder cancer.
  • To determine the impact of KMT2C downregulation on DNA damage response and repair pathways.
  • To explore therapeutic vulnerabilities in KMT2C-deficient bladder cancer.

Main Methods:

  • Analysis of KMT2C expression and its effects on epigenetic status in bladder cancer cells.
  • Assessment of DNA damage response and repair gene expression.
  • Evaluation of homologous recombination deficiency and sensitivity to PARP1/2 inhibition.

Main Results:

  • Downregulation of KMT2C in bladder cancer cells alters epigenetic profiles and DNA repair gene expression.
  • Cells with low KMT2C activity exhibit homologous recombination deficiency and increased endogenous DNA damage.
  • Genomic instability is significantly higher in KMT2C-low bladder cancer cells.

Conclusions:

  • KMT2C deficiency compromises DNA repair, leading to genomic instability in bladder cancer.
  • Bladder cancer cells with low KMT2C expression are hypersensitive to PARP1/2 inhibitors.
  • Targeting KMT2C-deficient bladder cancers with PARP1/2 inhibitors like olaparib presents a promising therapeutic strategy.